MarketPulse

MHRA

2 articles
BenzingaBenzinga··Prnewswire

Soligenix's SGX945 Earns UK Innovative Medicine Designation for Behçet's Disease

Soligenix's SGX945 earns UK Promising Innovative Medicine designation for Behçet's Disease, enabling early patient access with Phase 2 data showing 40% ulcer improvement.
SNGXrare diseaseBehçet's Disease
BenzingaBenzinga··Business Wire

Savara Clears FDA Hurdle for MOLBREEVI as Drug Advances Toward Autoimmune PAP Approval

Savara receives FDA Day 74 Letter for MOLBREEVI with no advisory committee meeting planned. PDUFA target date set for August 2026.
SVRAFDA approvalMOLBREEVI